Stem cell transplantation for the Wiskott–Aldrich syndrome: a single-center experience confirms efficacy of matched unrelated donor transplantation
Authors:
- 2 October 2006
- journal article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 38 (10) , 671-679
Abstract
The treatment of Wiskott–Aldrich syndrome (WAS), a once uniformly fatal disorder, has evolved considerably as the use of hematopoietic stem cell transplant has become more widespread. For the majority of patients who lack an human leukocyte antigen-identical sibling, closely matched unrelated donor bone marrow transplant (MUD BMT) at an early age is an excellent option that nevertheless is not uniformly chosen. We retrospectively analyzed our experience with transplantation in 23 patients with WAS from 1990 to 2005 at the University of Brescia, Italy, of whom 16 received MUD BMT. Myeloablative chemotherapy was well tolerated with median neutrophil engraftment at day 18, and no cases of grade III or IV graft-vs-host disease. Overall survival was very good with 78.2% (18/23) of the whole cohort and 81.2% (13/16) of MUD BMT recipients surviving. Among 18 survivors, full donor engraftment was detected in 12 patients, and stable mixed chimerism in all blood lineages in four patients. Deaths were limited to patients who had received mismatched related BMT or who had severe clinical symptomatology at the time of transplantation, further emphasizing the safety and efficacy of MUD BMT when performed early in the clinical course of WAS.Keywords
This publication has 29 references indexed in Scilit:
- Efficacy of Gene Therapy for Wiskott-Aldrich Syndrome Using a WAS Promoter/cDNA-Containing Lentiviral Vector and Nonlethal IrradiationHuman Gene Therapy, 2006
- Hematopoietic stem cell transplantation in Omenn syndrome: a single-center experienceBone Marrow Transplantation, 2005
- Lentiviral vectors transcriptionally targeted to hematopoietic cells by WASP gene proximal promoter sequencesGene Therapy, 2005
- Defects in T-cell–mediated immunity to influenza virus in murine Wiskott-Aldrich syndrome are corrected by oncoretroviral vector–mediated gene transfer into repopulating hematopoietic cellsBlood, 2003
- Gene therapy for Wiskott-Aldrich syndrome: rescue of T-cell signaling and amelioration of colitis upon transplantation of retrovirally transduced hematopoietic stem cells in miceBlood, 2002
- Retrovirus-Mediated WASP Gene Transfer Corrects Wiskott-Aldrich Syndrome T-Cell DysfunctionHuman Gene Therapy, 2002
- Defective actin polymerization in EBV-transformed B-cell lines from patients with the Wiskott-Aldrich syndromeThe Journal of Pathology, 1998
- Bone marrow transplantation in 26 patients with Wiskott-Aldrich syndrome from a single centerThe Journal of Pediatrics, 1996
- Marrow transplantation from human leukocyte antigen-identical or haploidentical donors for correction of Wiskott-Aldrich syndromeThe Journal of Pediatrics, 1991
- Complete Correction of the Wiskott-Aldrich Syndrome by Allogeneic Bone-Marrow TransplantationNew England Journal of Medicine, 1978